Osmium Partners Boosted By $456,000 Its Intersections (INTX) Stake; Sonoma Pharmaceuticals (SNOA) Shorts Decreased By 5.51%

May 25, 2017 - By Michael Collier

Osmium Partners Llc increased Intersections Inc (INTX) stake by 4.59% reported in 2016Q4 SEC filing. Osmium Partners Llc acquired 152,000 shares as Intersections Inc (INTX)’s stock rose 42.58%. The Osmium Partners Llc holds 3.46 million shares with $13.82M value, up from 3.31 million last quarter. Intersections Inc now has $113.88M valuation. The stock declined 1.44% or $0.07 reaching $4.78 on the news. About 18,196 shares traded. Intersections Inc. (NASDAQ:INTX) has risen 108.61% since May 25, 2016 and is uptrending. It has outperformed by 91.91% the S&P500.

Sonoma Pharmaceuticals Incorporated (NASDAQ:SNOA) had a decrease of 5.51% in short interest. SNOA’s SI was 85,800 shares in May as released by FINRA. Its down 5.51% from 90,800 shares previously. With 17,300 avg volume, 5 days are for Sonoma Pharmaceuticals Incorporated (NASDAQ:SNOA)’s short sellers to cover SNOA’s short positions. The SI to Sonoma Pharmaceuticals Incorporated’s float is 2.05%. About 7,124 shares traded. Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has risen 35.93% since May 25, 2016 and is uptrending. It has outperformed by 19.23% the S&P500.

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical firm that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company has market cap of $29.34 million. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. It currently has negative earnings. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue.

Investors sentiment increased to 0.82 in Q4 2016. Its up 0.22, from 0.6 in 2016Q3. It increased, as 3 investors sold INTX shares while 8 reduced holdings. 4 funds opened positions while 5 raised stakes. 6.58 million shares or 2.42% less from 6.74 million shares in 2016Q3 were reported. Creative Planning has invested 0% in Intersections Inc. (NASDAQ:INTX). Nationwide Fund Advisors accumulated 2,144 shares. Loeb Prns invested in 49,145 shares. 18,079 are held by Bancorporation Of Mellon Corp. Morgan Stanley holds 0% or 2,725 shares in its portfolio. Manufacturers Life Insur The stated it has 0% in Intersections Inc. (NASDAQ:INTX). Barclays Public Ltd reported 0% stake. Northern Trust Corporation holds 0% or 22,073 shares. Bancorporation Of America De reported 16 shares. Menta Cap Llc accumulated 0.04% or 109,489 shares. Moreover, Blackrock Inv Mgmt Limited Liability Company has 0% invested in Intersections Inc. (NASDAQ:INTX) for 1,265 shares. Renaissance Techs Ltd Liability Corp holds 0.01% or 906,000 shares. Moreover, Ims Cap Mgmt has 0.06% invested in Intersections Inc. (NASDAQ:INTX) for 15,147 shares. Susquehanna Group Limited Liability Partnership reported 0% stake. Raymond James Finance Service Advisors has 0% invested in Intersections Inc. (NASDAQ:INTX) for 17,500 shares.

Since December 8, 2016, it had 2 insider purchases, and 3 selling transactions for $857,030 activity. The insider Roets Johan sold 40,000 shares worth $216,800. MCGOUGH DAVID A had bought 200,000 shares worth $680,000. Shares for $104,074 were sold by STANFIELD MICHAEL R. Another trade for 152,000 shares valued at $536,011 was bought by Osmium Partners – LLC.